Global Cancer Immunotherapies

Cancer Immunotherapies Comprehensive Study by End-User (Healthcare Sector, Pharmaceutical, Cancer Research Centre, Laboratory, Others), Cancer Type (Bladder Cancer, Brain Cancer, Cervical Cancer, Head and Neck Cancer, Others) Players and Region - Global Market Outlook to 2028

Cancer Immunotherapies Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Cancer Immunotherapies Market Scope
Immunotherapies is a treatment that uses certain parts of a person's immune system to fight diseases such as cancer. It can be done in various ways stimulating or boosting. It is a type of biological therapy. Biological therapy is a type of treatment that uses substances made from living organisms to treat cancer.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAmerican Cancer Society (United States), WebMD (United States), Amgen, Inc. (United States), Astrazeneca, PLC (United Kingdom), Bayer AG (Germany), Bristol-Myers Squibb Company (United States), Eli Lily And Company (United States), Pfizer, Inc. (United States), Merck KGAA (Germany) and Novartis AG (Switzerland)
CAGR%


Companies in the market are concentrating on cancer treatment. North America is the fastest-growing country in cancer disease and infections due to the rise in the healthcare sector, increased focus healthcare system, an increased incidence of cancer. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cancer Immunotherapies market throughout the predicted period.

American Cancer Society (United States), WebMD (United States), Amgen, Inc. (United States), Astrazeneca, PLC (United Kingdom), Bayer AG (Germany), Bristol-Myers Squibb Company (United States), Eli Lily And Company (United States), Pfizer, Inc. (United States), Merck KGAA (Germany) and Novartis AG (Switzerland) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Cancer Immunotherapies market by Type and Region with country level break-up.

On the basis of geography, the market of Cancer Immunotherapies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies

In November 2022, Elranatamab, an experimental cancer immunotherapy, was given Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of persons with relapsed or refractory multiple myeloma (RRMM), according to Pfizer Inc.


Market Growth Drivers:
Factors such as increased in the healthcare sector, rise in cancer disease, and surge in technological advancements in cancer treatment therapies

Challenges:
Improve the effectiveness and patient response rates

Restraints:
An increasing number of infections and diseases

Opportunities:
Rapidly increasing number of cancer patient’s propel the growth of the market during the forecast period

Key Target Audience
Research & Development, Healthcare Industry and Laboratory Centres

Report Objectives / Segmentation Covered

By End-User
  • Healthcare Sector
  • Pharmaceutical
  • Cancer Research Centre
  • Laboratory
  • Others

By Cancer Type
  • Bladder Cancer
  • Brain Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Factors such as increased in the healthcare sector, rise in cancer disease, and surge in technological advancements in cancer treatment therapies
    • 3.3. Market Challenges
      • 3.3.1. Improve the effectiveness and patient response rates
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Immunotherapies, by End-User, Cancer Type and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Immunotherapies (Value)
      • 5.2.1. Global Cancer Immunotherapies by: End-User (Value)
        • 5.2.1.1. Healthcare Sector
        • 5.2.1.2. Pharmaceutical
        • 5.2.1.3. Cancer Research Centre
        • 5.2.1.4. Laboratory
        • 5.2.1.5. Others
      • 5.2.2. Global Cancer Immunotherapies by: Cancer Type (Value)
        • 5.2.2.1. Bladder Cancer
        • 5.2.2.2. Brain Cancer
        • 5.2.2.3. Cervical Cancer
        • 5.2.2.4. Head and Neck Cancer
        • 5.2.2.5. Others
      • 5.2.3. Global Cancer Immunotherapies Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Cancer Immunotherapies (Price)
  • 6. Cancer Immunotherapies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. American Cancer Society (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. WebMD (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astrazeneca, PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lily And Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck KGAA (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Immunotherapies Sale, by End-User, Cancer Type and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Immunotherapies (Value)
      • 7.2.1. Global Cancer Immunotherapies by: End-User (Value)
        • 7.2.1.1. Healthcare Sector
        • 7.2.1.2. Pharmaceutical
        • 7.2.1.3. Cancer Research Centre
        • 7.2.1.4. Laboratory
        • 7.2.1.5. Others
      • 7.2.2. Global Cancer Immunotherapies by: Cancer Type (Value)
        • 7.2.2.1. Bladder Cancer
        • 7.2.2.2. Brain Cancer
        • 7.2.2.3. Cervical Cancer
        • 7.2.2.4. Head and Neck Cancer
        • 7.2.2.5. Others
      • 7.2.3. Global Cancer Immunotherapies Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Cancer Immunotherapies (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Immunotherapies: by End-User(USD Million)
  • Table 2. Cancer Immunotherapies Healthcare Sector , by Region USD Million (2017-2022)
  • Table 3. Cancer Immunotherapies Pharmaceutical , by Region USD Million (2017-2022)
  • Table 4. Cancer Immunotherapies Cancer Research Centre , by Region USD Million (2017-2022)
  • Table 5. Cancer Immunotherapies Laboratory , by Region USD Million (2017-2022)
  • Table 6. Cancer Immunotherapies Others , by Region USD Million (2017-2022)
  • Table 7. Cancer Immunotherapies: by Cancer Type(USD Million)
  • Table 8. Cancer Immunotherapies Bladder Cancer , by Region USD Million (2017-2022)
  • Table 9. Cancer Immunotherapies Brain Cancer , by Region USD Million (2017-2022)
  • Table 10. Cancer Immunotherapies Cervical Cancer , by Region USD Million (2017-2022)
  • Table 11. Cancer Immunotherapies Head and Neck Cancer , by Region USD Million (2017-2022)
  • Table 12. Cancer Immunotherapies Others , by Region USD Million (2017-2022)
  • Table 13. South America Cancer Immunotherapies, by Country USD Million (2017-2022)
  • Table 14. South America Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 15. South America Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 16. Brazil Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 17. Brazil Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 18. Argentina Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 19. Argentina Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 20. Rest of South America Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 21. Rest of South America Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 22. Asia Pacific Cancer Immunotherapies, by Country USD Million (2017-2022)
  • Table 23. Asia Pacific Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 24. Asia Pacific Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 25. China Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 26. China Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 27. Japan Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 28. Japan Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 29. India Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 30. India Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 31. South Korea Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 32. South Korea Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 33. Taiwan Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 34. Taiwan Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 35. Australia Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 36. Australia Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 37. Rest of Asia-Pacific Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 38. Rest of Asia-Pacific Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 39. Europe Cancer Immunotherapies, by Country USD Million (2017-2022)
  • Table 40. Europe Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 41. Europe Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 42. Germany Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 43. Germany Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 44. France Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 45. France Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 46. Italy Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 47. Italy Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 48. United Kingdom Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 49. United Kingdom Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 50. Netherlands Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 51. Netherlands Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 52. Rest of Europe Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 53. Rest of Europe Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 54. MEA Cancer Immunotherapies, by Country USD Million (2017-2022)
  • Table 55. MEA Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 56. MEA Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 57. Middle East Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 58. Middle East Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 59. Africa Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 60. Africa Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 61. North America Cancer Immunotherapies, by Country USD Million (2017-2022)
  • Table 62. North America Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 63. North America Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 64. United States Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 65. United States Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 66. Canada Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 67. Canada Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 68. Mexico Cancer Immunotherapies, by End-User USD Million (2017-2022)
  • Table 69. Mexico Cancer Immunotherapies, by Cancer Type USD Million (2017-2022)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Cancer Immunotherapies: by End-User(USD Million)
  • Table 81. Cancer Immunotherapies Healthcare Sector , by Region USD Million (2023-2028)
  • Table 82. Cancer Immunotherapies Pharmaceutical , by Region USD Million (2023-2028)
  • Table 83. Cancer Immunotherapies Cancer Research Centre , by Region USD Million (2023-2028)
  • Table 84. Cancer Immunotherapies Laboratory , by Region USD Million (2023-2028)
  • Table 85. Cancer Immunotherapies Others , by Region USD Million (2023-2028)
  • Table 86. Cancer Immunotherapies: by Cancer Type(USD Million)
  • Table 87. Cancer Immunotherapies Bladder Cancer , by Region USD Million (2023-2028)
  • Table 88. Cancer Immunotherapies Brain Cancer , by Region USD Million (2023-2028)
  • Table 89. Cancer Immunotherapies Cervical Cancer , by Region USD Million (2023-2028)
  • Table 90. Cancer Immunotherapies Head and Neck Cancer , by Region USD Million (2023-2028)
  • Table 91. Cancer Immunotherapies Others , by Region USD Million (2023-2028)
  • Table 92. South America Cancer Immunotherapies, by Country USD Million (2023-2028)
  • Table 93. South America Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 94. South America Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 95. Brazil Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 96. Brazil Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 97. Argentina Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 98. Argentina Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 99. Rest of South America Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 100. Rest of South America Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 101. Asia Pacific Cancer Immunotherapies, by Country USD Million (2023-2028)
  • Table 102. Asia Pacific Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 103. Asia Pacific Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 104. China Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 105. China Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 106. Japan Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 107. Japan Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 108. India Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 109. India Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 110. South Korea Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 111. South Korea Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 112. Taiwan Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 113. Taiwan Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 114. Australia Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 115. Australia Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 116. Rest of Asia-Pacific Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 117. Rest of Asia-Pacific Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 118. Europe Cancer Immunotherapies, by Country USD Million (2023-2028)
  • Table 119. Europe Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 120. Europe Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 121. Germany Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 122. Germany Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 123. France Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 124. France Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 125. Italy Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 126. Italy Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 127. United Kingdom Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 128. United Kingdom Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 129. Netherlands Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 130. Netherlands Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 131. Rest of Europe Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 132. Rest of Europe Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 133. MEA Cancer Immunotherapies, by Country USD Million (2023-2028)
  • Table 134. MEA Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 135. MEA Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 136. Middle East Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 137. Middle East Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 138. Africa Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 139. Africa Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 140. North America Cancer Immunotherapies, by Country USD Million (2023-2028)
  • Table 141. North America Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 142. North America Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 143. United States Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 144. United States Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 145. Canada Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 146. Canada Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 147. Mexico Cancer Immunotherapies, by End-User USD Million (2023-2028)
  • Table 148. Mexico Cancer Immunotherapies, by Cancer Type USD Million (2023-2028)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Immunotherapies: by End-User USD Million (2017-2022)
  • Figure 5. Global Cancer Immunotherapies: by Cancer Type USD Million (2017-2022)
  • Figure 6. South America Cancer Immunotherapies Share (%), by Country
  • Figure 7. Asia Pacific Cancer Immunotherapies Share (%), by Country
  • Figure 8. Europe Cancer Immunotherapies Share (%), by Country
  • Figure 9. MEA Cancer Immunotherapies Share (%), by Country
  • Figure 10. North America Cancer Immunotherapies Share (%), by Country
  • Figure 11. Global Cancer Immunotherapies share by Players 2022 (%)
  • Figure 12. Global Cancer Immunotherapies share by Players (Top 3) 2022(%)
  • Figure 13. Global Cancer Immunotherapies share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. American Cancer Society (United States) Revenue, Net Income and Gross profit
  • Figure 16. American Cancer Society (United States) Revenue: by Geography 2022
  • Figure 17. WebMD (United States) Revenue, Net Income and Gross profit
  • Figure 18. WebMD (United States) Revenue: by Geography 2022
  • Figure 19. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Amgen, Inc. (United States) Revenue: by Geography 2022
  • Figure 21. Astrazeneca, PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Astrazeneca, PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 27. Eli Lily And Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lily And Company (United States) Revenue: by Geography 2022
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Merck KGAA (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Merck KGAA (Germany) Revenue: by Geography 2022
  • Figure 33. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 35. Global Cancer Immunotherapies: by End-User USD Million (2023-2028)
  • Figure 36. Global Cancer Immunotherapies: by Cancer Type USD Million (2023-2028)
  • Figure 37. South America Cancer Immunotherapies Share (%), by Country
  • Figure 38. Asia Pacific Cancer Immunotherapies Share (%), by Country
  • Figure 39. Europe Cancer Immunotherapies Share (%), by Country
  • Figure 40. MEA Cancer Immunotherapies Share (%), by Country
  • Figure 41. North America Cancer Immunotherapies Share (%), by Country
List of companies from research coverage that are profiled in the study
  • American Cancer Society (United States)
  • WebMD (United States)
  • Amgen, Inc. (United States)
  • Astrazeneca, PLC (United Kingdom)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (United States)
  • Eli Lily And Company (United States)
  • Pfizer, Inc. (United States)
  • Merck KGAA (Germany)
  • Novartis AG (Switzerland)
Select User Access Type

Key Highlights of Report


May 2023 239 Pages 70 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Immunotherapies Quantitative research analysis
Global Cancer Immunotherapies Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Cancer Immunotherapies Market are by end use application [].
The Cancer Immunotherapies Market is gaining popularity and expected to see strong valuation by 2028.
  • Factors such as increased in the healthcare sector, rise in cancer disease, and surge in technological advancements in cancer treatment therapies

Know More About Global Cancer Immunotherapies Report?

Have a Query? Click Here

Other Related Reports

Central Venous Catheter Comprehensive Study by Type (Peripherally Inserted Central Venous Catheter, Tunneled Central Venous Catheter, Non-tunneled Central Venous Catheter), Application (Kidney Dialys...
$ 3750
Pancreatitis Drugs Comprehensive Study by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Drug Form (Tablets, Capsule), Pancreatitis (Acute Pancreatitis, Chronic Pancreatitis), End...
$ 3450
Glucomannan Extract Comprehensive Study by Type (Glucomannan 75%, Glucomannan 80%, Glucomannan 90%), Application (Food Industry, Pharmaceutical Industry, Healthy Products Industry), Form (Tablet, Pow...
$ 3450
Leuprolide Acetate Comprehensive Study by Type (Intramuscular, Subcutaneous), Application (Prostate Cancer, Precocious, Uterine Fibroid, Others) Players and Region - Global Market Outlook to 2027
$ 3500
Bromhexine Comprehensive Study by Application (Chronic Bronchitis, Asthma, Cough, Other), Form (Tablets, Syrup), Host (Oral, Injection), Dosage (48 mg/day, 96 mg/day, Others) Players and Region - Glo...
$ 3500
Metastatic Ovarian Cancer Drug Comprehensive Study by Type (E-7449, Crizotinib, CMB-305, G-305, LV-305, Others), Application (Clinic, Hospital, Others), Ovarian Cancer (Epithelial Ovarian Cancer, Str...
$ 3350